Information Provided By:
Fly News Breaks for February 19, 2020
Feb 19, 2020 | 08:49 EDT
BTIG analyst Thomas Shrader raised his price target on Esperion to $90 and kept his Buy rating going into this week's PDUFA deadline for its bempedoic acid, or BA. The analyst says his discussions with non-coastal lipidologists are keeping him excited about the "very high" price potential of the drug, though he sees the price as "not particularly patient-driven" but rather by payors who can make a drug like BA hard to get.
News For ESPR From the Last 2 Days
There are no results for your query ESPR